Clinical Trial Update: 2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients [Phase 3]

View source ↗

Summary

Phase 3 study comparing fixed combination CHF 5993 to Ultibro in COPD patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF 5993
• Ultibro (glycopyrronium/indacaterol)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED